Last reviewed · How we verify
Albuterol/salmeterol HFA MDI
Albuterol and salmeterol are beta-2 adrenergic agonists that relax airway smooth muscle to improve breathing, with albuterol providing rapid relief and salmeterol offering sustained bronchodilation.
Albuterol and salmeterol are beta-2 adrenergic agonists that relax airway smooth muscle to improve breathing, with albuterol providing rapid relief and salmeterol offering sustained bronchodilation. Used for Asthma maintenance and acute symptom relief, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Albuterol/salmeterol HFA MDI |
|---|---|
| Also known as | short-acting β2-adrenergic agonists |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Beta-2 adrenergic agonist combination (SABA/LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Albuterol is a short-acting beta-2 agonist (SABA) that rapidly binds to beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation within minutes. Salmeterol is a long-acting beta-2 agonist (LABA) with sustained activity over 12 hours. The combination provides both immediate symptom relief and maintenance bronchodilation for asthma and COPD management.
Approved indications
- Asthma maintenance and acute symptom relief
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers (PHASE4)
- A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer (PHASE1)
- Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects (PHASE2)
- Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: